Highlights Actinogen Medical Limited

Equities

ACW

AU000000ACW3

Delayed Australian S.E. Other stock markets 08:25:18 07/06/2024 am IST			5-day change	1st Jan Change
0.03 ^AUD	+3.45%		+3.45%	+36.36%

30/05	Actinogen Medical Completes AU$3.9 Million Non-Renounceable Entitlement Offer	MT
15/05	Actinogen Medical Opens AU$3.9 Million Entitlement Offer; Shares Down 7%	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Actinogen Medical Completes AU$3.9 Million Non-Renounceable Entitlement Offer	30/05	MT
Actinogen Medical Opens AU$3.9 Million Entitlement Offer; Shares Down 7%	15/05	MT
Rights Issue: 1 new share @ 0.025 AUD for 15 existing shares	09/05	FA
Actinogen Medical Raising Up to AU$8.9 Million for Advancing Trial, Working Capital; Shares Fall 24%	03/05	MT
Actinogen Medical Limited Announces the Full Enrolment of 167 Participants in the Company's XanaCIDD Phase 2A Clinical Trial in Patients with Cognitive Importive in Major Depressant Disorder	22/04	CI
Actinogen Medical Completes Patient Enrolment for XanaCIDD Phase 2a Trial; Shares Up 3%	22/04	MT
Actinogen Medical Limited Announces First Patient Treated in XanaMIA Phase 2b Alzheimer's Disease Trial	15/04	CI
Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation	26/03	MT
Actinogen Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2023	26/02	CI
Actinogen Medical Secures UK Innovation Passport for Alzheimer’s Disease Treatment	15/02	MT
Actinogen Medical Limited Announces Enrolment in the XanaCIDD Phase 2A Proof-Of-Concept Trial	28/11	CI
Actinogen Medical Receives AU$4.8 Million R&D Tax Refund	28/11	MT
Actinogen Medical Limited Announces CFO Changes	08/11	CI
AActinogen Medical Limited to Present Progress on Phase 2 Trials At the Bio Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease Conference, Boston	13/23/13	CI
Actinogen Medical Limited Announces Optimization of XanaMIA Phase 2b Trial in Patients with Mild-to-Moderate Alzheimer's Disease to Reduce Cost and Time to Initial Results	26/23/26	CI
Actinogen Medical Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30/23/30	CI
Rights Issue: 100 new shares @ 0.025 AUD for 454 existing shares	11/23/11	FA
Companies in Alzheimer's race after US nod for Eisai/Biogen drug	07/23/07	RE
Actinogen Medical Limited to Present Progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 Trials at the BIO International Convention	31/23/31	CI
Actinogen Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2022	22/23/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Actinogen Medical Limited

Equities

ACW

AU000000ACW3

Highlights

Filters